MedCity News
MAY 30, 2025
By treating model governance as a proactive, integral part of operations rather than a box to check after the fact, life sciences organizations can uphold compliance, better allocate their resources, and gain a competitive edge. The post Innovate or Stagnate: Overcoming Model Governance Challenges in Life Sciences appeared first on MedCity News.
PharmaVoice
MAY 30, 2025
An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 29, 2025
The HSS has terminated a contract previously awarded to Moderna to help advance a vaccine candidate targeting bird flu.
European Pharmaceutical Review
MAY 29, 2025
Research has illustrated a potential new device for harvesting T cells that could improve the cost-effectiveness of manufacturing CAR T-cell therapy and make the cancer immunotherapy more accessible to patients. In development by investigators in the US, the device, called capture and glow (CAPGLO), captures T cells via a magnetic field and makes them visible using glowing fluorescent tags.
Advertiser: ZoomInfo
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
MedCity News
MAY 27, 2025
Eli Lillys acquisition of SiteOne Therapeutics acquisition comes ahead of Phase 2 testing of the startups lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain. This target has clinical and regulatory validation from the recent FDA approval of Vertex Pharmaceuticals pain drug, Journavx. The post Eli Lilly Commits $1B to Get Drug That Could Rival Vertexs New Non-Opioid Pain Med appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaTimes
MAY 28, 2025
Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines to treat pain and other neuronal hyperexcitability disorders, to advance SiteOnes leading asset STC-004. Lilly will lead STC-004 through phase 2 trials and commercialisation for global markets.
Pharmaceutical Technology
MAY 28, 2025
Merck KGaA is filing for global regulatory approvals of pimicotinibafter it met primary and secondary endpoints in a Phase III TGCT trial.
MedCity News
MAY 28, 2025
Its time to debunk sustainability myths in health care and get to the heart of why sustainable supply chain practices are not only the right step forward, but also offer inherent advantages on the financial savings and patient satisfaction front. The post Sustainability as a Supply Chain Business Strategy: What Leaders Should Know appeared first on MedCity News.
pharmaphorum
MAY 28, 2025
InflaRx has abandoned its drug development programme, vilobelimab for rare skin disease pyoderma gangrenosum, cratering its share price.
Speaker: Jesse Hunter and Brynn Chadwick
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
PharmaTimes
MAY 26, 2025
Company secures regulatory approvals for commercial rollout in UK and US
Impetus Digital
MAY 26, 2025
A version of this article was previously published in the Journal of mHealth. Medical Science Liaisons (MSLs) play a pivotal role in bridging the gap between pharmaceutical companies and the medical community and are vital to the success of a company. Beyond ensuring that products are utilized effectively and serving as a scientific expert for the medical community, the primary role of MSLs involves establishing and maintaining peer-to-peer relationships with Key Opinion Leaders (KOLs) and other
MedCity News
MAY 30, 2025
Pfizer drug Braftovi achieved statistically significant and clinically meaningful improvement in overall survival for colorectal cancer patients in a Phase 3 clinical trial. The results will be presented Friday during the annual meeting of the American Society of Clinical Oncology. The post Precision Pfizer Drug Leads to Unprecedented Survival in Colorectal Cancer, Data at ASCO Show appeared first on MedCity News.
pharmaphorum
MAY 30, 2025
Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
PharmaTimes
MAY 29, 2025
The alliance combines Lumanitys commercial and development strategy capabilities with PICIs translational research expertise
European Pharmaceutical Review
MAY 30, 2025
New, 96-week trial data show that relapsing multiple sclerosis (RMS) patients given Roches Brutons tyrosine kinase (BTK) inhibitor maintained low levels of disease activity for up to two years. These results are from the Phase II FENopta open-label extension (OLE) study of oral fenebrutinib. The drug dually inhibits of both B-cell and microglia activation, which, according to Roche, may reduce both disease activity and disability progression.
MedCity News
MAY 29, 2025
Allowing hospitals to repair the equipment they depend upon daily is not a step backward, but a reaffirmation of trust in the skilled and deeply committed professionals who already maintain the integrity of our healthcare systems. The post Rebuttal: Medical Device Right to Repair is the Wrong Approach appeared first on MedCity News.
pharmaphorum
MAY 30, 2025
Astellas was the first company to bring a drug against the claudin target CLDN18.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaTimes
MAY 26, 2025
First non-immunosuppressive dual-action therapy approved for eligible patients
PharmaTech
MAY 28, 2025
Leveraging computerized maintenance management systems software can enhance efficiency, improve quality control, ensure accurate documentation, and strengthen data integrity.
MedCity News
MAY 28, 2025
Application rationalization shouldnt be a cleanup project it should be a pillar of the M&A investment thesis, with clear ROI tied to cost savings, risk mitigation, and innovation readiness. The post The Strategic Power of Application Rationalization in Healthcare M&A appeared first on MedCity News.
pharmaphorum
MAY 28, 2025
Teva gets fast-track status from the FDA for a coeliac disease drug with a mechanism that has proved tough to crack
Advertiser: ZoomInfo
ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!
PharmaTimes
MAY 28, 2025
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase agreement. Juno GmbH was previously owned by Bristol Myers Squibb. Financial terms have not been disclosed.
European Pharmaceutical Review
MAY 27, 2025
The Committee for Medicinal Products for Human Use (CHMP) has recommended ten medicines for approval in its latest meeting. The committee recommended authorisation of three cancer medicines. The first, aconditional approval of Aucatzyl (obecabtagene autoleucel), to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. Blenrep (belantamab mafodotin), a treatment for relapsed or refractory multiple myeloma was also granted a positive opinion.
MedCity News
MAY 30, 2025
May has seen a slew of executive hires, exits and layoffs across the healthcare industry. For example, the American Medical Association and TigerConnect named new CEOs, and Google and UnitedHealth Group have seen key executives leave their roles. There were also layoffs at organizations including Devoted Health and New York-Presbyterian. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on MedCity News.
pharmaphorum
MAY 27, 2025
Roche is moving its antibiotic zosurabalpin into phase 3 for CRAB, potentially a big step forward in the fight against antimicrobial resistance
Speaker: Kevin Burke
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
Pharmacy Times
MAY 28, 2025
Pre-treatment DPYD genotyping significantly reduces hospitalizations and costs for patients with cancer, enhancing safety and efficiency in oncology care.
Pharmaceutical Technology
MAY 27, 2025
The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids.
MedCity News
MAY 30, 2025
Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellass antibody drug Vyloy became the first FDA-approved therapy for this target. The post Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug appeared first on MedCity News.
Expert insights. Personalized for you.
276 
Let's personalize your content